Abstracts tagged "Scleroderma, Systemic"

Abstract Number: 2463 • ACR Convergence 2024
Interstitial Lung Disease in Very Early Systemic Sclerosis – a Clinical and Radiological Characterization
Sinziana Muraru¹, Christian Blüthgen², Cosimo Bruni¹, Carina Mihai¹, Anna-Maria Hoffmann-Vold³, Muriel Elhai⁴, Mike Becker⁵, Thomas Frauenfelder⁶, Oliver Distler⁷ and Rucsandra Dobrota¹, ¹University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Institute for Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴University Hospital zurich, Zürich, Switzerland, ⁵Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ⁶University Hospital Zurich, Zurich, Zurich, Switzerland, ⁷Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: Interstitial lung disease (ILD) occurs in about 50% of patients with systemic sclerosis (SSc). The aims of this study were to assess the prevalence…
Abstract Number: 0683 • ACR Convergence 2024
Prognostic Value of Systemic Sclerosis-associated Primary Heart Involvement
Caya Gharibian¹, Vanessa Lupi¹, Alexander Gotschy¹, Mike Becker², Rucsandra Dobrota¹, Muriel Elhai³, Sinziana Muraru¹, Suzana Jordan¹, Anna-Maria Hoffmann-Vold⁴, Oliver Distler⁵, Robert Manka¹, Cosimo Bruni¹ and Carina Mihai¹, ¹University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ³University Hospital zurich, Zürich, Switzerland, ⁴Oslo University Hospital, Oslo, Norway, ⁵Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: A definition of primary heart involvement (pHI) in systemic sclerosis (SSc) was recently developed (Bruni C et al. J Scleroderma Relat Disord. 2022;7:24-32). Cardiac…
Abstract Number: 1584 • ACR Convergence 2024
Efficacy of Tofacitinib in the Treatment of Early Diffuse Cutaneous Systemic Sclerosis: A Clinical Study in Bangladesh
Md Zahid Amin¹, Nabil Amin khan², Prof. Md. Abu Shahin², Dr. Md. Ariful Islam², Prof. Md. Nazrul Islam², Prof. Syed Atiqul Haq³, Prof. Minhaj Rahim Choudhury³ and Prof. Mohammad Mostafa Zaman⁴, ¹Central Police Hospital, Dhaka, Dhaka, Bangladesh, ²BSMMU, Dhaka, Dhaka, Bangladesh, ³Department of Rheumatology, BSMMU, Dhaka, Dhaka, Bangladesh, ⁴Department of Public Health and Informatics, BSMMU, Dhaka, Dhaka, Bangladesh
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis, vascular abnormalities, and immune system dysregulation. Current treatment options are limited, and there…
Abstract Number: 2472 • ACR Convergence 2024
Are Anti-centromere Antibodies (aCENP) Predictive of Systemic Sclerosis Development in Patients Without Raynaud´s Phenomenon?
Andrea Alvear-Torres¹, María José Martínez-Becerra², María Carmen Vegas-Sánchez³, Sheila Recuero-Díaz¹, María Pérez-ferro⁴ and Olga Sánchez-Pernaute⁵, ¹Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ²Department of Immunology. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ³Hospital Universitario Fundación Jiménez Díaz and IIS-FJD, Madrid, Spain, ⁴Department of Rheumatology. Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁵Department of Rheumatology and Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz and IIS-FJD. Autonomous University of Madrid, Madrid, Spain
Background/Purpose: Anti-centromere (aCENP) antibodies are considered highly specific of systemic sclerosis (SSc), typically defining a limited cutaneous phenotype, usually associated to Raynaud´s phenomenon (RP). It…
Abstract Number: 0684 • ACR Convergence 2024
The Diagnostic Accuracy of Ultrasound for Low Muscle Mass in Women with Systemic Sclerosis
Lucas Dória¹, Vanessa Hax², André Mallmann², Rafaela Santo³, Leonardo Santos², Stephanie Pilotti², Daniel Moraes², Isabella Boening², Pedro Glanze², ODIRLEI MONTICIELO¹, Ricardo Xavier⁴ and Rafael Chakr⁵, ¹Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ²Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ³Health Research and Innovation Science Centre, Klaipeda University, Klaipeda, Lithuania, Porto Alegre, Rio Grande do Sul, Brazil, ⁴Universidade Federal do Rio Grande do Sul, Porto Alegre/RS, Rio Grande do Sul, Brazil, ⁵Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
Background/Purpose: Patients with systemic sclerosis (SSc) often experience body composition changes, including low muscle mass (myopenia), associated with physical disability, hospitalization and death. Our purpose…
Abstract Number: 1585 • ACR Convergence 2024
Characterization of the Fecal Metabolome in Early Systemic Sclerosis
Arissa Young¹, Kristofer Andreasson², Jen Labus³, Nedas Matulianos⁴, Blake Wilde¹, Jonathan Jacobs³, Heather Christofk⁴ and Elizabeth Volkmann⁵, ¹UCLA, Los Angeles, CA, ²Lund University, Lund, Sweden, ³UCLA, Los Angeles, ⁴University of California Los Angeles, Los Angeles, CA, ⁵University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles
Background/Purpose: Previous studies have shown that alterations in gut microbiota are present early in systemic sclerosis (SSc) (Andréasson et al. 2022) and are associated with…
Abstract Number: 2473 • ACR Convergence 2024
Criterion Validity of Modified Rodnan Skin Score: Does It Capture Skin Thickness or Hardening? Results of a Large Skin Histology Study
Shervin Assassi¹, Ruhani Desai², Jeffrey Browning³, Samuel Theodore¹, Meng Zhang¹, Brian Skaug¹, Jerry Alonso¹, Zsuzsanna McMahan¹, Maureen Mayes¹ and Minghua Wu¹, ¹UTHealth Houston Division of Rheumatology, Houston, TX, ²UTHealth Houston Division of Rheumatology, DeLand, FL, ³Boston University, Cambridge, MA
Background/Purpose: Modified Rodnan Skin Score is a widely used outcome measure for skin involvement in systemic sclerosis (SSc). Its criterion validity (comparison to the gold…
Abstract Number: 0702 • ACR Convergence 2024
AISA 021, a Novel Calcium Channel Antagonist in Development for Raynaud’s & Systemic Sclerosis, Has Antagonistic Activity at Sodium Channel Targets for Pain Relief and Treats Scleroderma Pain Better Than Current Calcium Channel Blockers in a Phase 2A Study
Andrew Sternlicht¹ and Meredith Todd², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia
Background/Purpose: Improved treatments for Raynaud's phenomenon in Systemic Sclerosis (SSc) are needed. A novel oral calcium channel blocker (cilnidipine), with N-type channel antagonism is being…
Abstract Number: 1591 • ACR Convergence 2024
Domains and Outcome Measures for the Assessment of Digital Vasculopathy and Raynaud Phenomenon in Juvenile Systemic Sclerosis: A Systematic Review
Valerio maniscalco¹, Simone Appenzeller², Jennifer lemon³, Lucy stead⁴, Natalia Vasquez Canizares⁵, Gabriele Simonini⁶, Suzanne Li⁷ and Clare Pain⁸, and IJOG study, ¹Santo Stefano Hospital; Meyer Children Hospital IRCCS, Firenze, Toscana, Italy, ²Unicamp, Campinas, SP, Brazil, ³Alder Hey Children's NHS Foundation Trust, Liverpool, ⁴Liverpool University, Liverpool, ⁵Children's Hospital at Montefiore; Albert Einstein College of Medicine;, New York, NY, ⁶Meyer Children Hospital IRCCS; NEUROFARBA Department, University of Florence, Florence, Italy, ⁷Hackensack University Medical Center, Hackensack, ⁸Alderhey Children's NHS Foundation Trust, Liverpool, United Kingdom
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan autoimmune disease that primary affect the vascular system determining multiple organ damage and reducing quality of life…
Abstract Number: 2477 • ACR Convergence 2024
Quantifying Tissue Microstructural Changes in Scleroderma Skin Using a Novel, Point-of-care, High-frequency-ultrasound Instrument
Kimberly Lakin¹, Cameron Hoerig², Jessica Gordon³, Elmira Ghahramani², Mia Diaz¹, Robert Spiera⁴, dana Orange⁵ and Jonathan Mamou², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medical College, New York, NY, ³Division of Rheumatology, Weill Cornell Medical College, New York, NY, ⁴Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, ⁵Rockefeller University, New York, NY
Background/Purpose: A highly reproducible, quantitative method of measuring skin severity in systemic sclerosis (SSc) trials and patient care is needed. While conventional skin US, operating…
Abstract Number: 0706 • ACR Convergence 2024
Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension
Carleigh Zahn¹, Scott Visovatti², Rosemary Gedert¹, Suiyuan Huang¹, Victor Moles¹, Amber Young¹, Vallerie McLaughlin¹ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²The Ohio State University, Columbus
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of mortality in systemic sclerosis (SSc). We launched an IRB approved prospective study (NOVEL) in 2013 at…
Abstract Number: 1691 • ACR Convergence 2024
Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease
Elizabeth Volkmann¹, Holly Wilhalme², Donald Tashkin², Grace Kim², Jonathan Goldin², Alana Haussmann², Masataka Kuwana³, Michael Roth² and Shervin Assassi⁴, ¹University of California, Department of Medicine, Los Angeles, CA, USA, Los Angeles, ²UCLA, Los Angeles, ³Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ⁴UTHealth Houston Division of Rheumatology, Houston, TX
Background/Purpose: Despite the expanding treatment landscape for systemic sclerosis-associated interstitial lung disease (SSc-ILD), the lack of early and valid treatment response biomarkers (measurable in the…
Abstract Number: 2641 • ACR Convergence 2024
Identification of Systemic Sclerosis Intrinsic Subtypes in the ASSET Clinical Trial Using PBC Gene Expression
Zhiyun Gong¹, Timothy Sullivan², Tammara Wood³, David Fox⁴, Dinesh Khanna⁵ and Michael Whitfield⁶, ¹Dartmouth College, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Dartmouth, Hanover, NH, ⁴University of Michigan, Dexter, MI, ⁵University of Michigan, Ann Arbor, MI, ⁶Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic sclerosis (SSc) is molecularly heterogeneous and distinct subtypes of patients have been identified based on gene expression in skin. Although treatments have improved,…
Abstract Number: 0708 • ACR Convergence 2024
Outcomes of Intermittent Intravenous Steroid Use During Infusion Therapy in Systemic Sclerosis
Vangala Adarsh¹, dihowm Fatma¹, Eyerusalem Akpan², Meredith Keller², Maheswari Muruganandam², N. Suzanne Emil², Frank O'Sullivan³, Roderick Fields² and wilmer sibbitt¹, ¹UNM, Albuquerque, NM, ²University of New Mexico, Albuquerque, NM, ³University of New Mexico School of Medicine, Albuquerque, NM
Background/Purpose: Use of high dose corticosteroids in systemic sclerosis (SSc) is considered a significant risk factor for development of scleroderma renal crisis (SRC). Intravenous (IV)…
Abstract Number: 1829 • ACR Convergence 2024
Genomic Analysis of Skin Biopsies Differentiates Major Anti-Nuclear Autoantibody Subsets in Limited Cutaneous Systemic Sclerosis
Philip Yee¹, Medha Kanitkar², Kristina Clark³, Voon Ong¹ and Christopher Denton⁴, ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom, ³University of Oxford, Oxford, United Kingdom, ⁴University College London, Northwood, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) displays significant heterogeneity. Those with limited cutaneous systemic sclerosis (lcSSc) experience significant systemic organ involvement similar to those with diffuse cutaneous…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].